A Six Week Pharmacokinetic Study of TP-03 in Healthy Subjects

Healthy Clinical Trial

Official title:

Pharmacokinetic Study to Evaluate the Whole Blood Pharmacokinetics of TP-03 Following Six Week Topical Ocular Administration

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05138861
• Other study ID #: TRS-012
• Status: Completed
• Phase: Phase 1
• Start date: February 9, 2021
• Est. completion date: September 3, 2021

Study information

• Verified date: April 2024
• Source: Tarsus Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Pharmacokinetic Study to Evaluate the Whole Blood Pharmacokinetics of TP-03 Following Six Week Topical Ocular Administration.

Description:

This is a single-center, open-label, single-arm study. A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye. The doses of Days 1, 2 (morning), 41 (evening), and 42 will be self-administered under supervision of the site staff at the clinical site. All remaining doses will be self-administered at home. Throughout the study, PK blood samples will be collected and safety assessments will be performed.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 3, 2021
• Est. primary completion date: September 3, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Provision of signed and dated informed consent form (ICF)

2. Stated willingness to comply with all study procedures and availability for the duration of the study

3. Healthy adult male or female

4. If female, meets one of the following criteria:

1. Is of childbearing potential and agrees to use an acceptable contraceptive method. Or

2. Male partner has had a vasectomy less than 6 months prior to dosing and the female subject agrees to use an additional acceptable contraceptive method from the first study drug administration until 112 days after the last study drug administration Or

3. Is of non-childbearing potential, defined as surgically sterile (ie, has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or is in a post-menopausal state (ie, at least 1 year without menses without an alternative medical condition prior to the first study drug administration)

5. Aged at least 18 years

6. Non- or ex-smoker (An ex-smoker is defined as someone who completely stopped using nicotine products for at least 180 days prior to the first study drug administration)

7. Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an Investigator

Exclusion Criteria:

1. Female who is lactating

2. Female who is pregnant according to the pregnancy test at screening or prior to the first study drug administration

3. Presence or history of significant gastrointestinal, liver or kidney disease, or surgery that may affect drug bioavailability

4. History of significant cardiovascular, pulmonary, hematologic, neurological, psychiatric, endocrine, immunologic or dermatologic disease

5. Significant history of drug dependency or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic)

6. Any clinically significant illness in the 28 days prior to the first study drug administration

7. Use of any prescription drugs (with the exception of hormonal contraceptives or hormone replacement therapy) in the 28 days prior to the first study drug administration

8. Use of St. John's wort in the 28 days prior to the first study drug administration

9. History of any ocular surgery or laser within the past 12 months prior to the first study drug administration

10. Have used artificial eyelashes, eyelash extensions or had other cosmetic eyelash or eyelid procedures (e.g., eyeliner tattooing, eyelash tinting, eyelash curling perm, etc.) within 7 days prior to Screening or unwilling to forego their use during the study

11. Presence of clinically significant ocular surface diseases including blepharitis, dry eye, corneal scars, and pterygium, or any ocular abnormalities identified at Screening

12. Presence of acute ocular infection or inflammation at Screening, or required use of eye drops

13. Any history of tuberculosis

14. Positive screening results to HIV Ag/Ab combo, hepatitis B surface antigen or hepatitis C virus tests

15. Intake of an Investigational Product (IP) in the 28 days prior to the first study drug administration

16. Donation of 50 mL or more of blood in the 28 days prior to the first study drug administration

17. Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the 56 days prior to the first study drug administration

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• TP-03 (Lotilaner Ophthalmic Solution), 0.25%
A single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 1 and then twice a day (in the morning and in the evening, approximately 12 hours apart) starting on Day 2 for 40 consecutive days (Days 2 to 41). Thereafter, a single drop of the ophthalmic solution will be instilled in each eye on the morning of Day 42, for a total of 82 consecutive doses administered in each eye.

Locations

Country	Name	City	State
Canada	Altasciences	Mount Royal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Tarsus Pharmaceuticals, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Cmax at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Tmax at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Tlag at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner AUC0-168 at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner AUC0-2880 at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner AUC0-t at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner AUC0-inf at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner CL/F at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Vz/F at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner eff at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Thalf at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner ?z at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner AUC%extrap at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner MRT0-t at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Rac at various times	42 Days
Primary	To evaluate the concentration of lotilaner in blood multiple doses of TP-03, 0.25% in whole blood following topical ocular administration in healthy adult subjects for 42 days.	The primary PK endpoints following single and multiple dose administration will include whole blood PK parameters for lotilaner Ctrough at various times	42 Days
Primary	Incidence of treatment emergent adverse events (TEAEs)	Safety will be evaluated through the incidence rate of TEAEs	42 Days
Primary	Clinically significant changes from Baseline chemistry laboratory tests	Evaluate the safety of TP-03 through clinically significant changes from Baseline chemistry laboratory tests	42 Days
Primary	Clinically significant changes from Baseline hematology laboratory tests	Evaluate the safety of TP-03 through clinically significant changes from Baseline hematology laboratory tests	42 Days
Primary	Clinically significant changes from Baseline physical examinations	Safety will be evaluated through review of clinically significant changes in physical examinations from Baseline	42 Days
Primary	Clinically significant changes from Baseline electrocardiograms (ECGs)	Safety will be evaluated through review of clinically significant changes in electrocardiograms from Baseline	42 Days
Primary	Clinically significant changes from Baseline vitals	Safety will be evaluated through review of clinically significant changes from Baseline vital signs (including temperature [degrees Celsius], pulse rate [beats per minute], respiration rate [breaths per minute], and changes in systolic and diastolic blood pressure [mmHg]) from Baseline	42 Days
Primary	Clinically significant changes from Baseline corrected distance visual acuity	Safety will be evaluated through review of clinically significant changes in corrected distance visual acuity from Baseline	42 Days
Primary	Clinically significant changes from Baseline non-mydriatic fundus photographs	Safety will be evaluated through review of clinically significant changes in non-mydriatic fundus photographs from Baseline	42 Days
Primary	Clinically significant changes from Baseline intraocular pressure (IOP) measurement	Safety will be evaluated through review of clinically significant changes in IOP from Baseline	42 Days